What is PharmaIN?
PharmaIN Corporation operates at the intersection of advanced biotechnology and patient-centric care. The company specializes in the development of first- and best-in-class subcutaneous therapies, specifically targeting complex pathologies such as liver disease and oncology. Central to its value proposition is a sophisticated peptide engineering technology that enables the transformation of difficult-to-administer drugs into self-injectable formats. This innovation is designed to enhance patient autonomy and improve therapeutic outcomes for individuals suffering from advanced liver cirrhosis. With its lead candidate, PHIN-214, currently navigating the rigors of clinical trials, PharmaIN is transitioning from a research-heavy organization to a clinical-stage powerhouse capable of disrupting standard-of-care protocols.
How much funding has PharmaIN raised?
PharmaIN has raised a total of $1.6M across 2 funding rounds:
Private Equity
$1.5M
Debt
$150K
Private Equity (2014): $1.5M, investors not publicly disclosed
Debt (2020): $150K led by PPP
Key Investors in PharmaIN
Undisclosed Investor
A private equity firm focused on long-term capital appreciation and strategic growth in the life sciences sector.
PPP
Public-Private Partnership
Undisclosed Investor
An institutional investor specializing in early-to-mid stage biotech ventures with a focus on innovative drug delivery platforms.
What's next for PharmaIN?
Looking ahead, PharmaIN is strategically positioned to capitalize on its clinical momentum. The recent influx of capital will be instrumental in advancing PHIN-214 through critical trial milestones, providing the necessary runway to generate high-quality efficacy data. Management is actively pursuing strategic partnerships, which will likely serve as a catalyst for global distribution and commercialization efforts. As the company matures, the focus will shift toward regulatory engagement and the potential expansion of its peptide platform into additional therapeutic indications. By maintaining a disciplined approach to clinical development and leveraging its unique intellectual property, PharmaIN is well-equipped to navigate the complexities of the biopharmaceutical landscape and deliver long-term value to stakeholders.
See full PharmaIN company page
